Mantle Cell Lymphoma

The Food and Drug Administration granted a priority review to KTE-X19 for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

Lee Greenberger, chief scientific officer at the Leukemia and Lymphoma Society, discusses the basics of mantle cell lymphoma – including symptoms, diagnosis and advancing treatment options.

Neena Kennedy, from the Leukemia and Lymphoma Society, offers advice on how to find out about and join clinical trials.

Here is a list of the recent trial initiations that occurred within the cancer space in January.

Typically, the longer a patient with cancer is exposed to a drug the more side effects they experience, but in the case of Imbruvica, the opposite appears to be true for patients with MCL.

The pivotal phase 3 GRAVITAS-301 study – designed to evaluate itacitinib in combination with corticosteroids in patients with treatment-naïve acute graft-versus-host disease – failed to meet its primary endpoint of improving overall response rates.
 

Treatment with a CAR-T cell therapy showed promise in patients with mantle cell lymphoma, potentially leading to a new option for a group of individuals who have exhausted other options.

However, the recent addition of new chemotherapy-free options such as chimeric antigen receptor (CAR)-T cell therapy could offer hope for patients with mantle cell lymphoma who develop resistance to chemotherapy-based treatment.

While chemotherapy is widely used in the frontline treatment of mantle cell lymphoma (MCL), earlier use of BTK inhibitors such as Imbruvica (ibrutinib) may soon make chemotherapy obsolete for some patients, according to new data presented at the 2019 American Society of Hematology (ASH) Annual Meeting.

The Food and Drug Administration approved Brukinsa to treat relapsed and refractory mantle cell lymphoma, but what does this mean for patients?